I disagree with the other poster who thought SA Neop article was well written. IMO, this was a one sided hatchet job intended to drive the pps down. His analysis of the Lymphoseek pricing and current stock valuation was the only part that I can't call complete garbage. Other than that, it was hardly a fair assessment. We won't have to wait long to see who is right.
What a business, he shorts the stock then gets to write the hatchet job that gives him his chance to cover.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.